



---

# Endoscopic Third Space Applications for the Treatment of Obesity

---

CHRISTOPHER C. THOMPSON MD MSC FAGA FACG FASGE FJGS  
DIRECTOR OF ENDOSCOPY, BRIGHAM AND WOMEN'S HOSPITAL  
CO-DIRECTOR CENTER FOR WEIGHT MANAGEMENT AND WELLNESS  
PROFESSOR OF MEDICINE, HARVARD MEDICAL SCHOOL

IFSO Napoli 2023

# Disclosures

---


**BlueFlame Healthcare** – Founder, General Partner  
**ELLES** – Founder, Consultant, Board of Directors  
**Enterasense Ltd** – Founder, Consultant, Board of Directors  
**EnVision Endoscopy** – Founder, Consultant, Board of Directors  
**GI Windows Surgical** – Founder, Consultant, Board of Directors

**ColubrisMX** – Consultant (Scientific Advisory Board)  
**Covidien/Medtronic** – Consultant (Scientific Advisory Board)  
**FujiFilm** – Consultant (Scientific Advisory Board), Institutional Research Grant

**Apollo Endosurgery** – Institutional Research Grant  
**Boston Scientific** – Consultant (Consulting fees)/Research Support (Institutional Research Grant)  
**ERBE** – Institutional Research Grant  
**Fractyl** – Consultant/Advisory Board Member  
**GI Dynamics** – Institutional Research Grant  
**Lumendi** – Consultant/Institutional Research Grant  
**Olympus** – Consultant (Consulting Fees)/Research Support (Equipment Loans)  
**USGI Medical** – Institutional Research Grant

# Third Space Endoscopy

## Tissue Resection: ESD / STER



**ESD: 1) Mark 2) Lift 3) Incision 4) Dissection**






**STER: 1) Inject / access 2) Tunnel 3) Dissect 4) Close**

# Third Space Endoscopy

## Tunneled Myotomies

---



# Third Space Endoscopy

## Intersection with Bariatric Endoscopy

---

### Augment existing EBMTs

- Tissue preparation to promote healing
- Adding additional mechanism of action

### Creation of new bariatric procedures

- Addressing specific pathophysiology
- Altering normal physiology for a novel treatment effect

# Third Space Endoscopy

## Bariatric Procedures

Tissue preparation to promote healing


- Fistula closure (**EFTR Fistula Take Down**)
- RYGB revision (**ESD-TORe**)

Addressing specific pathophysiology

- Treatment of sleeve gastrectomy stenosis (**Tunneled Stricturectomy**)

Altering normal physiology for a unique treatment effect

- Additional mechanism of action for an existing EBMT (**GEM**)
- Novel primary EBMT (**BEAM**)



# Tissue Preparation

## Gastrogastric Fistula



95 patients with GGF

Avg 2.2 sutures placed



- 95% initial closure rate
- 65% re-open at avg 177 days
- Fistula < 1 cm predicts better response with durable closure in over 30% (mean f/u 395 days)

No fistula over 2 cm remained closed



# Tissue Preparation

## Gastrogastric Fistula - EFTR with Fistula Take Down





# Tissue Preparation

## TORe for Revision of RYGB

---

Factors important for good outcomes

- Tissue preparation
- Suture depth and type of apposition
- Suture pattern
- Final outlet size






# Endoscopic Suturing for Transoral Outlet Reduction Increases Weight Loss After Roux-en-Y Gastric Bypass Surgery

CHRISTOPHER C. THOMPSON,<sup>1</sup> BIPAN CHAND,<sup>2</sup> YANG K. CHEN,<sup>3</sup> DANIEL C. DEMARCO,<sup>4</sup> LARRY MILLER,<sup>5</sup> MICHAEL SCHWEITZER,<sup>6</sup> RICHARD I. ROTHSTEIN,<sup>7</sup> DAVID B. LAUTZ,<sup>8</sup> JAMES SLATTERY,<sup>1</sup> MICHELE B. RYAN,<sup>1</sup> STACY BRETHAUER,<sup>9</sup> PHILLIP SCHAUER,<sup>9</sup> MACK C. MITCHELL,<sup>10</sup> ANTHONY STARPOLI,<sup>11</sup> GREGORY B. HABER,<sup>11</sup> MARC F. CATALANO,<sup>12</sup> STEVEN EDMUNDOWICZ,<sup>13</sup> ANNETTE M. FAGNANT,<sup>14</sup> LEE M. KAPLAN,<sup>15</sup> and MITCHELL S. ROSLIN<sup>16</sup>



3.5% TWL

## RESTORE Trial – Sham controlled RCT with 6 month crossover



Analysis population	Primary outcomes analyses: percentage weight lost from baseline			
	TORe LS mean (95% CI)	Sham control LS mean (95% CI)	Treatment difference <sup>a</sup>	
			LS Mean (95% CI)	P value
ITT population: LOCF	3.5 (1.8-5.3)	0.4 (-2.3 to 3.0)	3.2 (0.5-5.9)	.021
ITT population: only patients completing study	3.8 (1.8-5.8)	0.3 (-2.8 to 3.3)	3.5 (0.6-6.5)	.020
As treated population: only patients completing study	3.9 (1.9-5.9)	0.2 (-2.8 to 3.2)	3.7 (0.8-6.6)	.014

# Comparison of a superficial suturing device with a full-thickness suturing device for transoral outlet reduction (with videos)

Nitin Kumar, MD, Christopher C. Thompson, MD

6% TWL

59 consecutive patients FT TORe matched to 59 of 129 ST TORe


TABLE 1. Baseline characteristics (matched cohort)

	Superficial (n = 59)	Full-thickness (n = 59)	P value
Sex,* no.	3 M/56 F	15 M/44 F	< .01
Age, y	48.8 ± 1.1†	49.9 ± 1.3	.52
Diabetes mellitus, %	17.2	23.7	.49
Lost weight regained, %	32.5 ± 3.0	40.9 ± 3.2	.06
Weight regained, kg	18.7 ± 1.8	18.6 ± 1.5	.97
Before TORe BMI	40.4 ± 1.0	41.1 ± 1.3	.67
Before TORe GJA, mm	24.3 ± 0.8	24.8 ± 0.9	.68
Before TORe pouch, mm	51.8 ± 1.5	49.7 ± 2.4	.46

M, Male; F, female; TORe, transoral outlet reduction; BMI, body mass index; GJA, gastrojejunal anastomosis.

\*Statistical significance.

†(Mean ± SEM)



# Transoral outlet reduction: a comparison of purse-string with interrupted stitch technique





Allison R. Schulman, MD, MPH,<sup>1,2</sup> Nitin Kumar, MD,<sup>3</sup>  
Christopher C. Thompson, MD, MSc, FASGE, FACP, AGAF<sup>1,2</sup>



8.6% TWL

Analysis of a prospective registry including 241 patients (purse string (PS) 187, interrupted (I) 54)



12 months - PS vs I  
 %TWL (8.6 vs 6.4, P 0.02)  
 %EWL (19.8 vs 11.7, P < .001)  
 %RWL (40.2 vs 27.8, P 0.02)  
 Total weight loss (9.5 vs 7.8, P 0.04)


TABLE 3. Results from univariable and multivariable regression analyses

Risk factors	Univariate analysis		Multivariable analysis	
	Beta estimate	P value	Adjusted beta estimate	P value
Age, y	-.02 ± .05	NS	.02 ± .10	NS
Male, n	1.93 ± .61	NS	2.34 ± 1.59	NS
Percent regain after initial RYGB	.03 ± .01	<.01*	.03 ± .01	<.01*
Technique (interrupted = reference)	3.20 ± 1.23	.01*	3.51 ± 1.26	<.01*
Pre-GJA size	-.19 ± .21	NS	.05 ± .09	NS

# Five-year outcomes of transoral outlet reduction for the treatment of weight regain after Roux-en-Y gastric bypass



**GIE**  
GASTROINTESTINAL ENDOSCOPY


Pichamol Jirapinyo, MD, MPH,<sup>1</sup> Nitin Kumar, MD,<sup>2</sup> Mohd Amer AlSamman, MD,<sup>3</sup>  
Christopher C. Thompson, MD, MSc<sup>1</sup>



331 patients with baseline BMI of  $40 \pm 9 \text{ kg/m}^2$

Efficacy at 5 years: **8.8% TWL (62% maintained 5% TWL)**





1/60 ⊗  
AVE ⊙

S1: F/T  
S2: LM  
S3: POP  
S4: REC

EG-760R  
3G402G060

\*   
HT NR  
SE   
フ



 BL-7000

4

# Endoscopic submucosal dissection with suturing for the treatment of weight regain after gastric bypass: outcomes and comparison with traditional transoral outlet reduction (with video)

Pichamol Jirapinyo, MD, MPH,<sup>1,2</sup> Diogo T. H. de Moura, MD, PhD,<sup>1,2,3</sup> Christopher C. Thompson, MD, MSc<sup>1,2</sup>

**12% TWL**



**Matched based on GJA and pouch sizes**

# Third Space Endoscopy

## Bariatric Procedures

Tissue preparation to promote healing


- Fistula closure (EFTR Fistula Take Down)
- RYGB revision (ESD-TORe)

Addressing specific pathophysiology

- Treatment of sleeve gastrectomy stenosis (Tunneled Stricturectomy)

Altering normal physiology for a unique treatment effect

- Additional mechanism of action for an existing EBMT (GEM)
- Novel primary EBMT (BEAM)






# Sleeve Gastrectomy Stenosis **Tunneled Stricturotomy**

Retrospective Review (n=13)

Primary endpoint: clinical success (symptom improvement, resumption of adequate oral intake, no further regurgitation / emesis intervention)

Excessive weight loss and malnutrition

- Helical GSS (85%)
- Prior GSS treatment (77%)
- No SAEs
- Intra-procedural complications (mucosal tears = 2)
- Clinical Success (Median 175 days): 77%
- Change in GCSI: 2.06 (IQR 1.5–2.8) to 0.39 (IQR 0.2–0.5)
- Surgical Revision: 23%



# Third Space Endoscopy

## Bariatric Procedures

Tissue preparation to promote healing


- Fistula closure (EFTR Fistula Take Down)
- RYGB revision (ESD-TORe)

Addressing specific pathophysiology

- Treatment of sleeve gastrectomy stenosis

Altering normal physiology for a unique treatment effect

- Additional mechanism of action for an existing EBMT (GEM)
- Novel primary EBMT (BEAM)




# Gastric Physiology

---

Digestive physiology is critical to the understanding of endoscopic bariatric and metabolic therapies

Gastric motility:

- Storage: fundal accommodation
- Mixing: churning and breakdown of food into chyme
- Emptying: pump function of the distal body and antrum



# Gastric Physiology

## Bariatric Procedure Proposed Mechanisms of Action

---

Gastric interventions used to treat obesity work by interfering with the digestion of food and are typically thought to alter gastric motility



# Gastroplasty with Endoscopic Myotomy (GEM)

We propose a novel procedure that affects several aspects of gastric motility in an effort to produce greater and more durable weight loss

## Gastroplasty with Endoscopic Myotomy (GEM)

### Step 1: Pylorus-sparing antral myotomy


- Via a submucosal tunneling technique
- To weaken the antral pump

### Step 2: A running suture (belt)

- At the incisura to separate the antrum from gastric body
- To minimize tension on the myotomy access site


### Step 3: Endoscopic sleeve gastroplasty (ESG)

- To reduce mixing and limit accommodation



# Gastroplasty With Endoscopic Myotomy for the Treatment of Obesity: Preliminary Efficacy and Physiologic Results

Christopher C. Thompson, Pichamol Jirapinyo, Raj Shah, and Cem Simsek



Pylorus-sparing Antral Myotomy

## Gastroplasty with Endoscopic Myotomy (GEM)



N=6

At 1, 3 and 6 months, patients experienced  $11.5 \pm 2.9\%$ ,  $14.8 \pm 2.5\%$  and  $19.5 \pm 1.4\%$  TWL ( $p < 0.0001$  for all)

100% of patients experienced  $\geq 10\%$  TWL

### Gastric Emptying Breath Test (GEBT)

- Proportion of patients with delayed gastric emptying: 1/6 (17%)  $\rightarrow$  6/6 (100%) ( $p=0.02$ )
- Average T1/2 increased from  $90 \pm 58$  minutes to  $204 \pm 18$  minutes ( $p < 0.0001$ )



### Gastroparesis Cardinal Symptom Index (GCSI)

- Total GCSI:  $0.4 \pm 0.4 \rightarrow 0.6 \pm 0.3$  ( $p=0.63$ )
- Postprandial fullness/early satiety subscale:  $0.2 \pm 0.3 \rightarrow 1.0 \pm 0.5$  ( $p=0.01$ )
- Nausea/vomiting subscale:  $0 \rightarrow 0.1 \pm 0.3$  ( $p=0.36$ )
- Bloating subscale:  $1.6 \pm 1.3 \rightarrow 0.3 \pm 0.4$  ( $p=0.10$ )

# GEM

Gastroplasty with  
Endoscopic Myotomy

1/60 ⊗  
Lv+5 AUTO ⊗

HT NR

↗  
↘

2.4

5.8  
5.9

☐ \*

S1: F/T  
S2: LM  
S3: EZOOM  
S4: TRIG

EG-740N


1G399G085

☀ BL-7000X




# Bariatric Endoscopic Antral Myotomy (BEAM)


Mean % total weight loss by month post-BEAM<sup>1</sup>



Mean GCSI subscore pre and post-myotomy<sup>1</sup>



Gastric emptying rate pre and 3 months post BEAM<sup>2</sup>



1) Sa1897 Bariatric Endoscopic Antral Myotomy (BEAM): Technical Feasibility and Preliminary Results of a Novel Weight Loss Procedure  
 Authors: Christopher C. Thompson, Roberto Trasolini, Pichamol Jirapinyo. DDW 2023 abstract library


2) Unpublished data\*





# Future Third Space EBMTs

## Robotics



# Conclusion

---

Third space techniques are making their way into bariatric endoscopy

These techniques appear to offer improved durability, greater weight loss, less variability, and potentially lower cost

Training and certification processes are the next hurdles to broader adoption of these techniques

# Thank you!



@MetabolicEndo

